Physician profile

Barry O Conlan

Family Medicine · Toledo, OH

NPI 1568462158

$4,294.87

in general payments reported to CMS, 2019-2025

38 companies · $811 in 2025

The $811 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,597.04

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $750.76 2021-2025 Ozempic, Rybelsus, Wegovy
Abbvie INC. $618.90 2021-2025 Vraylar, Ubrelvy, Qulipta
Astrazeneca Pharmaceuticals LP $373.33 2021-2025 Breztri, Airsupra, Farxiga
Pfizer INC. $367.73 2021-2025
Glaxosmithkline, LLC. $223.85 2022-2025 Trelegy Ellipta, Arexvy, Shingrix
Lilly USA, LLC $221.99 2021-2025 Mounjaro, Zepbound, Jardiance
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $184.90 2021-2025 Xifaxan
Welch Allyn $117.71 2021
Baxter Healthcare $117.71 2022
Astellas Pharma US INC $113.86 2021-2025 Veozah
Boehringer Ingelheim Pharmaceuticals, INC. $113.61 2020-2022
Exact Sciences Corporation $102.49 2023-2025 Cologuard Collection Kit, The Cologuard Plus Collection Kit
Abbott Laboratories $90.23 2021-2025 Freestyle Libre 3
Axsome Therapeutics, INC. $88.31 2023-2024 Auvelity, Sunosi
Bayer Healthcare Pharmaceuticals INC. $86.50 2021-2022
Show all 38 companies
CompanyGeneral paymentsYearsTop products
Biogen, INC. $80.84 2021-2022
Merck Sharp & Dohme LLC $57.80 2021-2025 Capvaxive, Gardasil 9
Dexcom, INC. $51.26 2023-2025 Dexcom G6 Transmitter
Takeda Pharmaceuticals U.S.A., INC. $46.46 2021-2022
Horizon Therapeutics Plc $46.04 2021-2022
Corcept Therapeutics $44.42 2025 Korlym
Biohaven Pharmaceuticals, INC. $41.57 2021
Kowa Pharmaceuticals America, INC. $36.63 2022
Shield Therapeutics INC $33.04 2023 Accrufer
Endo Pharmaceuticals INC. $32.90 2021
Almatica Pharma LLC $30.83 2021
Idorsia Pharmaceuticals US INC $30.31 2022-2023 Quviviq
Sunovion Pharmaceuticals INC. $23.99 2022
Xeris Pharmaceuticals, INC. $22.42 2024 Gvoke Hypopen
E.R. Squibb & Sons, L.L.C. $19.29 2023 Eliquis
Lundbeck LLC $17.60 2024 Rexulti
Novartis Pharmaceuticals Corporation $17.04 2022
Biohaven Pharmaceutical Holding Company LTD. $16.45 2022
Antares Pharma, INC. $16.10 2024 Xyosted
Amgen INC. $15.28 2025 Otezla, Repatha
Sumitomo Pharma America, INC. $15.06 2025 Gemtesa
Corium, LLC $14.80 2025 Azstarys
Mylan Specialty L.P. $12.86 2023 Yupelri

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Barry O Conlan

$4,294.87

in general payments reported 2019-2025

Years
2020-2025
Top company
Novo Nordisk INC
Context
The $811 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/721349/barry-o-conlan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.